This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Acorda Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Acorda Therapeutics.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	42.4%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Acorda Therapeutics no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

DB:CDG - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2023	117	-21	-11	-11	N/A
3/31/2023	118	-58	-14	-14	N/A
12/31/2022	119	-66	-21	-21	N/A
9/30/2022	124	-106	-27	-27	N/A
6/30/2022	122	-119	-34	-34	N/A
3/31/2022	123	-95	-28	-28	N/A
12/31/2021	129	-104	-42	-41	N/A
9/30/2021	130	-166	-44	-43	N/A
6/30/2021	152	-132	-37	-37	N/A
3/31/2021	154	-127	-51	-49	N/A
12/31/2020	153	-100	-65	-61	N/A
9/30/2020	165	49	-92	-74	N/A
6/30/2020	160	-222	-133	-95	N/A
3/31/2020	176	-232	-157	-89	N/A
12/31/2019	192	-273	-219	-128	N/A
9/30/2019	211	-329	-216	-129	N/A
6/30/2019	306	-79	-107	-27	N/A
3/31/2019	409	-6	-9	45	N/A
12/31/2018	471	34	117	151	N/A
9/30/2018	591	-147	197	224	N/A
6/30/2018	589	-158	181	197	N/A
3/31/2018	575	-213	138	151	N/A
12/31/2017	588	-223	83	97	N/A
9/30/2017	541	-55	56	69	N/A
6/30/2017	535	-43	10	23	N/A
3/31/2017	523	-53	N/A	3	N/A
12/31/2016	520	-35	N/A	30	N/A
9/30/2016	510	-22	N/A	25	N/A
6/30/2016	522	-6	N/A	42	N/A
3/31/2016	509	14	N/A	54	N/A
12/31/2015	493	11	N/A	38	N/A
9/30/2015	480	2	N/A	29	N/A
6/30/2015	437	10	N/A	46	N/A
3/31/2015	421	14	N/A	61	N/A
12/31/2014	401	18	N/A	75	N/A
9/30/2014	376	24	N/A	81	N/A
6/30/2014	355	19	N/A	62	N/A
3/31/2014	345	18	N/A	51	N/A
12/31/2013	336	16	N/A	39	N/A
9/30/2013	325	143	N/A	37	N/A
6/30/2013	318	145	N/A	37	N/A
3/31/2013	306	146	N/A	41	N/A
12/31/2012	306	155	N/A	52	N/A
9/30/2012	297	35	N/A	68	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de CDG es superior a la tasa de ahorro (0.4%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de CDG crezcan más rápidamente que el mercado German

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de CDG crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de CDG crezcan más rápidamente que el mercado de German.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de CDG crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CDG se prevé que sea elevada dentro de 3 años.

This company listing is no longer active

Acorda Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

Recent updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.

Motion for Joint Administration Filed by Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing

First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A Hearing

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027

Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock Market

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings released: US$1.93 loss per share (vs US$3.53 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)

Independent Director Barry Greene has left the company

Independent Director Catherine D. Strader has left the company

Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)

First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)

Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021

Revenue beats expectations

Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)

Acorda Therapeutics Announces Executive Changes

Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR).

Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic Index

Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million.

New 90-day high: €5.42

Third quarter 2020 earnings released: EPS US$0.15

Revenue beats expectations

New 90-day high: €0.89

Acorda Therapeutics, Inc. to Report Q3, 2020 Results on Nov 03, 2020

Steven M. Rauscher to Resign as Member of Board of Directors of Acorda Therapeutics, Inc

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from S&P Global BMI Index

New 90-day low - €0.40

New 90-day low - €0.50

First half earnings released

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Value Index

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento